PRP use in cartilage disease (arthritis) | Orthopedic Associates

By John Urse, DO

In a randomized, controlled trial , Level of Evidence 1(best), Patel, et al, (reference 1), divided patients into 3 groups:

  • Group A-52 Osteoarthritis (OA) knees, single Platelet-Rich Plasma (PRP) injection
  • Group B: 50 OA knees, 2 injections
  • Group C- 46 OA knees, single saline placebo (control) injection.

All PRP was White Blood Cell (WBC)-poor PLT count 300% of whole blood values. Results: All WOMAC (knee pain rating scale) parameters improved significantly in Group A, B within 2-3 weeks, lasting to 6 months follow-up. Lesser grades of arthritis did better, and 22% of Group A patients had mild complications (nausea, dizziness), while 44% of Group B had mild complications.

Conclusion: Both groups treated with a leukocyte-poor Platelet-Rich Plasma (LR-PRP) had significantly superior results compared to control (placebo) patients. Results declined after 6 months. Single dose as effective as two injections.

Patel,et al,Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, randomized, double-blind trial. Am J Sports Med 2013; 41 (2): 356-364.